On the mechanism of action of arsenoplatins: arsenoplatin-1 binding to a B-DNA dodecamer.
Dalton Trans
; 53(8): 3476-3483, 2024 Feb 20.
Article
em En
| MEDLINE
| ID: mdl-38270175
ABSTRACT
The reaction of Pt-based anticancer agents with arsenic trioxide affords robust complexes known as arsenoplatins. The prototype of this family of anticancer compounds is arsenoplatin-1 (AP-1) that contains an As(OH)2 fragment linked to a Pt(II) moiety derived from cisplatin. Crystallographic and spectrometric studies of AP-1 binding to a B-DNA double helix dodecamer are presented here, in comparison with cisplatin and transplatin. Results reveal that AP-1, cisplatin and transplatin react differently with the DNA model system. Notably, in the AP-1/DNA systems, the Pt-As bond can break down with time and As-containing fragments can be released. These results have implications for the understanding of the mechanism of action of arsenoplatins.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
DNA de Forma B
/
Trióxido de Arsênio
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article